Pfizer Signs $1B+ Licensing Deal with Medicus Pharma for CD228V

Key Facts

In a move that strengthens the innovative drug pipeline of major pharmaceutical players, Medicus Pharma has entered into a global licensing agreement with Pfizer to commercialize CD228V. This strategic partnership grants Pfizer exclusive rights to market the asset globally, leveraging the giant's extensive commercial infrastructure. According to reports, the deal is valued at over $1 billion and includes additional future royalties for Medicus Pharma based on commercial performance.

This agreement highlights the ongoing trend of mega-cap pharmaceutical firms expanding their portfolios through licensing deals with smaller biotech entities. Per market data, PFE stock stood at $29.02 (close September 2, 2026), having traded between a day low of $28.71 and a high of $29.09. While the deal is a significant catalyst for a smaller entity like Medicus Pharma, it represents a strategic asset addition for Pfizer's global commercial operations.

Investors are currently monitoring PFE price levels following its $29.02 close on September 2, 2026, with immediate support observed near the recent low of $28.71. As the economic calendar shows no immediate sector-specific catalysts in the coming days, market attention will likely shift toward the clinical and regulatory milestones of CD228V to gauge the long-term impact of this billion-dollar investment.